[Effects of Migu tablet on bone mineral density, serum matrix metalloproteinase-2 level and bone metabolic markers in postmenopausal osteoporosis].
OBJECTIVE
To study the effects of Migu tablet(MG) on bone mineral density (BMD), serum matrix metalloproteinase-2 (MMP-2) and bone metabolic markers in Chinese postmenopausal women.


METHODS
According to the criteria of osteoporosis, 192 Chinese postmenopausal female of the aged 55-62 were randomized into 4 groups, such as the normal, MG group, XLGB group and Leli group. The serum MMP-2, bone alkaline phosphates (sBAP), osteocalcin (sOC), bone cross-linked C-telopeptides of type I collagen (sCTx) and urine bone cross-linked N-telopeptides of type I collagen (uNTx) were measured using ELISA. BMD were measured using dual energy X-ray absorptiometry before and after medication at 12 and 24 weeks.


RESULTS
After treatment, the values of BMD were significantly higher in MG and XLGB groups separately, otherwise lower in Leli and normal control groups. At the same time, serum MMP-2, sCTx, uNTx/Cr concentrations were significantly lower and sBAP, sOC concentrations were higher, but the concentrations in Leli and normal control groups were basically same to the value of before treatment.


CONCLUSIONS
The effects of MG tablet to treat the PMO were notable, just same to XLGB. But calcium tablet cannot play a role in the treatment of osteoporosis and do not prevent the loss of bone.
Dai
Yi
Y
Department of Traditional Chinese Medicine, Union Hospital of Huazhong Science and Technology University, Wuhan 430022, China. daiyifreeman@yahoo.com.cn
Shen
Lin
L
D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D015415:Biomarkers / Q000097:blood / Q000652:urine; D015519:Bone Density / Q000187:drug effects*; D024042:Collagen Type I / Q000097:blood / Q000652:urine; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000302:isolation & purification / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D020778:Matrix Metalloproteinase 2 / Q000097:blood*; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D015663:Osteoporosis, Postmenopausal / Q000097:blood / Q000503:physiopathology / Q000517:prevention & control*; D010455:Peptides / Q000097:blood / Q000652:urine; D008517:Phytotherapy; D010946:Plants, Medicinal / Q000737:chemistry; D013607:Tablets; D016896:Treatment Outcome
D015415:Biomarkers; D024042:Collagen Type I; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D010455:Peptides; D013607:Tablets; C052929:collagen type I trimeric cross-linked peptide; C533452:migu; D015675:Osteocalcin; D000469:Alkaline Phosphatase; D020778:Matrix Metalloproteinase 2